Oncothyreon initiates Phase 1 trial of PX-866 cancer compound

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nBELLEVUE, WA, June 17 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY)\ntoday announced enrollment of the first patient in a Phase 1 trial of PX-866\nin patients with advanced solid tumors. PX-866 is a small molecule compound\ndesigned to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), an\nimportant cell survival signaling pathway.\n\n\n"PX-866 is a potent inhibitor of PI-3K, a component of a critical pathway\nthat is activated in many types of cancer, leading to tumor growth and\nsurvival," said Lynn Kirkpatrick, Ph.D., Chief Scientific Officer of\nOncothyreon. "We believe that the mechanism of action of PX-866, which\nirreversibly inhibits PI-3K, will have pharmacokinetic and pharmacodynamic\nadvantages that will distinguish PX-866 in the competitive field of PI-3K\ninhibitors."\n\n\nThe Phase 1 trial is expected to enroll up to 63 patients with advanced\nmetastatic cancer who have failed or are intolerant of standard therapy.\nPatients will receive PX-866 orally once per day on days 1 through 5 and 8\nthrough 12 during a four-week treatment cycle. Primary objectives of the study\ninclude establishment of a maximum tolerated dose, evaluation of safety, and\nanalysis of the pharmacodynamic and pharmacokinetic profiles of PX-866.\n\n\n"The start of the PX-866 trial represents a significant milestone for\nOncothyreon, as we now have three active clinical programs underway for our\npromising small molecule inhibitors," said Robert L. Kirkman, M.D., President\nand CEO of Oncothyreon. "Together with our therapeutic vaccine programs, we\nhave successfully established a broad and diverse oncology pipeline targeting\nmultiple cancer indications with substantial unmet medical need, and we look\nforward to sharing the ongoing progress from these clinical programs with the\nmedical community and our investors."\n\n\nIn addition to the PX-866 trial, Oncothyreon is conducting a Phase 2\ntrial of PX-12, an inhibitor of thioredoxin-1, in advanced pancreatic cancer,\na Phase 1b trial of PX-12 in advanced metastatic cancer, and a Phase 1 trial\nof PX-478, a small molecule inhibitor of hypoxia inducible factor-1 alpha, in\npatients with advanced solid tumors or lymphomas. Oncothyreon's partner, Merck\nKGaA of Darmstadt, Germany, is conducting a Phase 3 trial of Stimuvax(R), an\ninve...

More updates from Cascade Copper Corp.